Ironwood Pharmaceuticals (IRWD) Change in Receivables (2010 - 2026)

Ironwood Pharmaceuticals has reported Change in Receivables for 17 years, with the latest figure at $59.1 million in Q1 2026.

• Quarterly Change in Receivables rose 240.31% year-over-year to $59.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $66.1 million (up 304.88% YoY) and the FY2025 annual result came in at -$35.1 million, up 25.59% from the prior year.
• Change in Receivables advanced to $59.1 million in Q1 2026 per IRWD's latest filing, from -$73.6 million in the prior quarter.
• Over five years, Change in Receivables peaked at $59.1 million in Q1 2026 and troughed at -$73.6 million in Q4 2025.
• A 5-year average of -$1.9 million and a median of $3.2 million in 2023 frame the typical range for Change in Receivables.
• The sharpest annual moves came in 2022 and 2025: Change in Receivables soared 4405.71% in 2022, then plunged 1395.27% in 2025.
• Over 5 years, Change in Receivables stood at -$937000.0 in 2022, then surged by 588.47% to $4.6 million in 2023, then increased by 24.19% to $5.7 million in 2024, then slumped by 1395.27% to -$73.6 million in 2025, then soared by 180.27% to $59.1 million in 2026.
• According to Business Quant data, Change in Receivables over the past three periods registered $59.1 million, -$73.6 million, and $34.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.